Zydus Lifesciences share news, announcements and annual reports
NSE: ZYDUSLIFEBSE: 532321Pharmaceuticals & BiotechnologyMid Cap
Zydus Lifesciences Limited · Formerly Cadila Healthcare · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 2000
Last close ₹1,245.50up ₹61.10 (5.16%)BSE ₹1,244.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,184.40.
30 Oct: open ₹1,190.00, high ₹1,248.90, low ₹1,182.00
52-week range of traded prices to 30 Oct 2026
₹835.50Low, 2 Apr 2026₹1,248.90High, 30 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,24,239 Cr114th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 27.53
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 24.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.08%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.7%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹535 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 19.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.40
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 36,60,70935.2% delivered
Zydus Lifesciences board meetings
113 filed, newest first. Page 2 of 3.
May 2018
25 May · Board meeting
Jan 2018
Oct 2017
Jul 2017
12 Jul · Board meeting
Jun 2017
27 Jun · Board meeting
May 2017
27 May · Board meeting
Apr 2017
Feb 2017
Jan 2017
Oct 2016
Jul 2016
May 2016
Apr 2016
Mar 2016
Jan 2016
Oct 2015
Jul 2015
Apr 2015
27 Apr · Board meeting
To consider amongst other agenda items: 1. To approve the audited stand-alone and consolidated financial results for the quarter / year ended on March 31, 2015 2. To recommend the dividend on equity shares of the Company for the financial year ended on March 31, 2015.
Jan 2015
20 Jan · Board meeting
To consider amongst other agenda items to approve the unaudited financial results for the quarter and nine months ended on December 31, 2014.
Oct 2014
13 Oct · Board meeting
To consider amongst other agenda items to approve the unaudited financial results for the quarter/ half-year ended on September 30, 2014. Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 1992, the Trading Window will remain close from October 27, 2014 to November 07, 2014 for all directors and designated officers of the Company.
Jul 2014
9 Jul · Board meeting
To consider amongst other agenda items to approve the unaudited financial results for the quarter ended on June 30, 2014. Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 1992, the Trading Window will remain close from July 21, 2014 to July 31, 2014 for all directors and designated officers of the Company.
May 2014
Jan 2014
20 Jan · Board meeting
To consider amongst other agenda items to approve the unaudited financial results for the quarter/nine months ended on December 31, 2013. Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI(Prohibition of inisder Trading) Regulations, 1992, the Trading Window will remain close from January 29, 2014 to February 08, 2014 for all Directors and designated officers of the Company.
Oct 2013
15 Oct · Board meeting
To consider amongst other agenda items to approve the unaudited financial results for the quarter/ half-year ended on September 30, 2013.
Aug 2013
22 Aug · Board meeting
To consider amongst other agenda items to consider and approve the audited merged accounts for the financial year ended on March 31, 2013.
Jul 2013
24 Jul · Board meeting
To consider amongst other agenda items to approve the unaudited financial results for the first quarter of the Current financial year ended on June 30, 2013.
May 2013
17 May · Board meeting
To consider amongst other agenda items : (1) To approve audited financial statements for the financial year ended on March 31, 2013; (2) To consider declaration of interim dividend on equity shares for the financial year ended on March 31, 2013.
Apr 2013
18 Apr · Board meeting
To consider a proposal for exploring the possibilities for merger of certain wholly owned subsidiary companies with the Company and to approve the draft Scheme of Amalgamation under section 391-394 of the Companies Act, 1956.
Jan 2013
16 Jan · Board meeting
To consider amongst others unaudited financial results for the quarter / nine months ended on December 31, 2012.
Oct 2012
15 Oct · Board meeting
To consider amongst other unaudited financial results for the quarter/ half-year ended on September 30, 2012.
Jul 2012
18 Jul · Board meeting
To consider amongst others unaudited financial results for the quarter ended June 30, 2012.
Apr 2012
20 Apr · Board meeting
To consider amongst others audited financial results for the year ended on March 31, 2012 and to recommend the dividend on equity shares for the year ended March 31, 2012.
Jan 2012
23 Jan · Board meeting
To consider amongst others unaudited financial results for the quarter / nine months ended on December 31 ,2011.
Oct 2011
17 Oct · Board meeting
To consider amongst other unaudited financial results for the quarter/ half-year ended September 30, 2011.
Jul 2011
6 Jul · Board meeting
To consider amongst others unaudited financial results for the quarter ended June 30, 2011.
Apr 2011
25 Apr · Board meeting
To consider amongst others audited financial results for the year ended on March 31, 2011 and recommend the dividend on equity shares for the year ended March 31, 2011.
Jan 2011
6 Jan · Board meeting
To consider amongst others unaudited financial results for the quarter/ nine months ended December 31, 2010.
Oct 2010
11 Oct · Board meeting
To consider amongst others unaudited financial results for the quarter/ half-year ended September 30, 2010.
Jul 2010
9 Jul · Board meeting
Inter alia, to consider unaudited financial results for the quarter ended June 30, 2010
Apr 2010
7 Apr · Board meeting
To consider amongst others audited financial results for the year ended March 31, 2010 and for recommendation of dividend.
Feb 2010
22 Feb · Board meeting
To Consider the proposal of issuing Bonus Equity shares.
Jan 2010
8 Jan · Board meeting
To consider, amongst others, unaudited financial results for the quarter / nine months period ended December 31, 2009.
Oct 2009
9 Oct · Board meeting
To consider amongst others unaudited financial results for the quarter/ half-year ended September 30, 2009.
Jul 2009
13 Jul · Board meeting
Meeting on 27 Jul 2009: “Unaudited Financial Results for the Qtr ended June 30, 2009”
Apr 2009
15 Apr · Board meeting
To consider amongst others audited financial results and for recommendation of dividend for the year ended March 31, 2009.